NASDAQ:SAVACassava Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cassava Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.37 -0.28 (-7.67 %) (As of 07/15/2020 01:27 PM ET) Add Compare Share Today's Range$3.26Now: $3.37▼$3.6250-Day Range$2.04MA: $2.75▼$3.6452-Week Range$1.03Now: $3.37▼$10.95Volume2.06 million shsAverage Volume3.45 million shsMarket Capitalization$83.51 millionP/E RatioN/ADividend YieldN/ABeta2.97 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Cassava Sciences has a potential upside of 322.3% from its current price of $3.32.Amount of Analyst CoverageCassava Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCassava Sciences has received 52 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCassava Sciences has received 54 “underperform” votes. (Add your “underperform” vote.)Community SentimentCassava Sciences has received 50.94% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cassava Sciences and other stocks. Vote “Outperform” if you believe SAVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SAVA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.70% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 24.24% of the stock of Cassava Sciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to decrease in the coming year, from ($0.26) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -14.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -14.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.10 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAVA Previous Symbol CUSIPN/A CIKN/A Webwww.cassavasciences.com Phone512-501-2444Debt Debt-to-Equity RatioN/A Current Ratio22.60 Quick Ratio22.60Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book3.34Profitability EPS (Most Recent Fiscal Year)($0.27) Net Income$-4,630,000.00 Net MarginsN/A Return on Equity-21.52% Return on Assets-20.42%Miscellaneous Employees9 Outstanding Shares24,780,000Market Cap$83.51 million Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable NASDAQ:SAVA Rates by TradingView Receive SAVA News and Ratings via Email Sign-up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions How has Cassava Sciences' stock been impacted by COVID-19 (Coronavirus)? Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SAVA stock has decreased by 21.8% and is now trading at $3.3150. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cassava Sciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cassava Sciences. When is Cassava Sciences' next earnings date? Cassava Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cassava Sciences. How were Cassava Sciences' earnings last quarter? Cassava Sciences Inc (NASDAQ:SAVA) issued its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.05) EPS for the quarter. View Cassava Sciences' earnings history. When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work? Cassava Sciences's stock reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split. What price target have analysts set for SAVA? 2 brokerages have issued 1-year price objectives for Cassava Sciences' stock. Their forecasts range from $12.00 to $16.00. On average, they anticipate Cassava Sciences' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 322.3% from the stock's current price. View analysts' price targets for Cassava Sciences. Has Cassava Sciences been receiving favorable news coverage? Media coverage about SAVA stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cassava Sciences earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about Cassava Sciences. Who are some of Cassava Sciences' key competitors? Some companies that are related to Cassava Sciences include Bicycle Therapeutics (BCYC), Neptune Wellness Solutions (NEPT), Affimed (AFMD), Osmotica Pharmaceuticals (OSMT), Rigel Pharmaceuticals (RIGL), Pivot Pharmaceuticals (PVOTF), Magenta Therapeutics (MGTA), Seres Therapeutics (MCRB), Liminal BioSciences (LMNL), Concert Pharmaceuticals (CNCE), Urovant Sciences (UROV), Avadel Pharmaceuticals (AVDL), AMAG Pharmaceuticals (AMAG), IDEAYA Biosciences (IDYA) and OrganiGram (OGI). View all competitors. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), DURECT (DRRX), Bristol-Myers Squibb (BMY), Synergy Pharmaceuticals (SGYP), Baidu (BIDU), Exelixis (EXEL), Novavax (NVAX) and Opko Health (OPK). Who are Cassava Sciences' key executives? Cassava Sciences' management team includes the following people: Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)Mr. Eric J. Schoen, Chief Financial Officer (Age 51)Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs What is Cassava Sciences' stock symbol? Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA." How do I buy shares of Cassava Sciences? Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cassava Sciences' stock price today? One share of SAVA stock can currently be purchased for approximately $3.32. How big of a company is Cassava Sciences? Cassava Sciences has a market capitalization of $82.15 million. The company earns $-4,630,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe. What is Cassava Sciences' official website? The official website for Cassava Sciences is www.cassavasciences.com. How can I contact Cassava Sciences? Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
